Stock DNA
Pharmaceuticals & Biotechnology
ILS 100,245 Million ()
8.00
NA
0.00%
2.01
33.89%
4.19
Revenue and Profits:
Net Sales:
15,057 Million
(Quarterly Results - Jun 2025)
Net Profit:
1,009 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
44.4%
0%
44.4%
6 Months
50.58%
0%
50.58%
1 Year
47.66%
0%
47.66%
2 Years
153.53%
0%
153.53%
3 Years
209.29%
0%
209.29%
4 Years
246.78%
0%
246.78%
5 Years
188.71%
0%
188.71%
Teva Pharmaceutical Industries Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.64%
EBIT Growth (5y)
4.46%
EBIT to Interest (avg)
3.23
Debt to EBITDA (avg)
4.44
Net Debt to Equity (avg)
2.39
Sales to Capital Employed (avg)
0.65
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
11.59%
ROE (avg)
25.11%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
3.20
EV to EBIT
9.72
EV to EBITDA
7.52
EV to Capital Employed
1.68
EV to Sales
2.05
PEG Ratio
0.47
Dividend Yield
NA
ROCE (Latest)
17.33%
ROE (Latest)
38.03%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot : Sep 2020
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
15,056.60
13,960.10
7.85%
Operating Profit (PBDIT) excl Other Income
4,229.30
3,352.70
26.15%
Interest
1,012.60
1,036.90
-2.34%
Exceptional Items
-1,574.40
-357.70
-340.15%
Consolidate Net Profit
1,009.00
794.80
26.95%
Operating Profit Margin (Excl OI)
221.20%
177.00%
4.42%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 7.85% vs -10.13% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 26.95% vs 178.07% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
61,114.70
58,447.60
4.56%
Operating Profit (PBDIT) excl Other Income
16,243.00
16,042.90
1.25%
Interest
3,483.30
3,839.20
-9.27%
Exceptional Items
-13,944.20
-10,440.80
-33.55%
Consolidate Net Profit
-7,251.60
-2,268.10
-219.72%
Operating Profit Margin (Excl OI)
201.60%
201.70%
-0.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.56% vs 16.64% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -219.72% vs 72.99% in Dec 2023






